Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMAND trial of atezolizumab + bevacizumab with selective TACE strategies in unresectable hepatocellular carcinoma
2024-512682-14-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Objective response rate. Planned start Apr 2020; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-512682-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512682-14-00.